Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: A mixed treatment comparison meta-analysis

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Sun, Feng ^a,b,c   Yu, Kai ^d   Yang, Zhirong ^a   Wu, Shanshan ^a   Zhang, Yuan ^a   Shi, Luwen ^b   Ji, Linong ^e   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

^d TIANJIN FIFTH CENTRAL HOSPITAL   (China)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; EXENDIN 4; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; VENOM;

ADULT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBASE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG POTENTIATION; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; RISK ASSESSMENT; RISK FACTOR; TIME;

DIABETES MELLITUS, TYPE 2; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NAUSEA; ODDS RATIO; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, GLUCAGON; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOMS; VOMITING;

MLCS; MLOWN;

EID: 84872766753     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/230624     Document Type: Review

References (82)

1. Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 2-s2.0-2342466734 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
2. Verspohl E. J., Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacology and Therapeutics 2009 124 1 113 138 2-s2.0-68949159829 10.1016/j.pharmthera.2009.06.002
3. Hansen K. B., Knop F. K., Holst J. J., Vilsbøll T., Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. International Journal of Clinical Practice 2009 63 8 1154 1160 2-s2.0-67749104112 10.1111/j.1742-1241.2009.02086.x
4. Pratley R. E., Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape General Medicine 2008 10 7, article 171 2-s2.0-50949113950
5. Zander M., Madsbad S., Madsen J. L., Holst J. J., Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β -cell function in type 2 diabetes: a parallel-group study. Lancet 2002 359 9309 824 830 2-s2.0-0037045845 10.1016/S0140-6736(02)07952-7 (Pubitemid 34233752)
6. Nauck M. A., Heimesaat M. M., Behle K., Holst J. J., Nauck M. S., Ritzel R., Hüfner M., Schmiegel W. H., Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 2002 87 3 1239 1246 2-s2.0-0036959991 10.1210/jc.87.3.1239 (Pubitemid 36121094)
7. Nielsen L. L., Young A. A., Parkes D. G., Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides 2004 117 2 77 88 2-s2.0-0347360186 10.1016/j.regpep.2003.10.028 (Pubitemid 38045329)
8. Neumiller J. J., Campbell R. K., Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy 2009 43 9 1433 1444 2-s2.0-69949083472 10.1345/aph.1M134
9. Matthews J. E., Stewart M. W., De Boever E. H., Dobbins R. L., Hodge R. J., Walker S. E., Holland M. C., Bush M. A., Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2008 93 12 4810 4817 2-s2.0-57349168543 10.1210/jc.2008-1518
10. Retterstøl K., Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert Opinion on Investigational Drugs 2009 18 9 1405 1411 2-s2.0-68849092593 10.1517/13543780903164205
11. Christensen M., Knop F. K., Holst J. J., Vilsboll T., Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009 12 8 503 513 2-s2.0-68549099651
12. Umpierrez G. E., Blevins T., Rosenstock J., Cheng C., Anderson J. H., Bastyr E. J. III, The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes, Obesity and Metabolism 2011 13 5 418 425 2-s2.0-79953035319 10.1111/j.1463-1326.2011. 01366.x
13. Amori R. E., Lau J., Pittas A. G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Journal of the American Medical Association 2007 298 2 194 206 2-s2.0-34447267513 10.1001/jama.298.2.194 (Pubitemid 47057766)
14. Byetta (Exenatide Injection) Prescribing Information 2007 San Diego, California Amylin Pharmaceuticals
15. Norris S. L., Lee N., Thakurta S., Chan B. K. S., Exenatide efficacy and safety: a systematic review. Diabetic Medicine 2009 26 9 837 846 2-s2.0-69249195769 10.1111/j.1464-5491.2009.02790.x
16. Shyangdan D. S., Royle P. L., Clar C., Sharma P., Waugh N. R., Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011 10 CD006423
17. Li W. X., Gou J. F., Tian J. H., Yan X., Yang L., Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Current Therapeutic Research 2010 71 4 211 238 2-s2.0-77958617703 10.1016/j.curtheres. 2010.08.003
18. Montanya E., Sesti G., A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clinical Therapeutics 2009 31 11 2472 2488 2-s2.0-74549177233 10.1016/j.clinthera.2009.11.034
19. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J. M., Gavaghan D. J., McQuay H. J., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996 17 1 1 12 2-s2.0-0029914622 10.1016/0197-2456(95)00134-4 (Pubitemid 26120810)
20. Keus F., Wetterslev J., Gluud C., Gooszen H. G., Van Laarhoven C. J. H. M., Robustness assessments are needed to reduce bias in meta-analyses that include zero-event randomized trials. American Journal of Gastroenterology 2009 104 3 546 551 2-s2.0-61949136504 10.1038/ajg.2008.22
21. Fleiss J. L., The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993 2 2 121 145 2-s2.0-0027754610
22. Higgins J. P. T., Thompson S. G., Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002 21 11 1539 1558 2-s2.0-0037098199 10.1002/sim.1186 (Pubitemid 34746062)
23. Lu G., Ades A. E., Combination of direct and indirect evidence in mixed treatment comparisons. Statistics in Medicine 2004 23 20 3105 3124 2-s2.0-5044221416 10.1002/sim.1875 (Pubitemid 39334902)
24. Ades A. E., Sculpher M., Sutton A., Abrams K., Cooper N., Welton N., Lu G., Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics 2006 24 1 1 19 2-s2.0-32044454664 10.2165/00019053-200624010- 00001 (Pubitemid 43197227)
25. Salanti G., Marinho V., Higgins J. P. T., A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. Journal of Clinical Epidemiology 2009 62 8 857 864 2-s2.0-67649303082 10.1016/j.jclinepi.2008.10.001
26. Spiegelhalter D. J., Best N. G., Carlin B. P., Van Der Linde A., Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society. Series B 2002 64 4 583 639 2-s2.0-0036435040 10.1111/1467-9868.00353
27. Salanti G., Ades A. E., Ioannidis J. P. A., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. Journal of Clinical Epidemiology 2011 64 2 163 171 2-s2.0-78650509651 10.1016/j.jclinepi.2010.03.016
28. Rosenstock J., Reusch J., Bush M., Yang F., Stewart M., Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009 32 10 1880 1886 2-s2.0-70349664297 10.2337/dc09-0366
29. Apovian C. M., Bergenstal R. M., Cuddihy R. M., Qu Y., Lenox S., Lewis M. S., Glass L. C., Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. American Journal of Medicine 2010 123 5 468.e9 468.e17 2-s2.0-77950827693 10.1016/j.amjmed.2009.11.019
30. Barnett A. H., Burger J., Johns D., Brodows R., Kendall D. M., Roberts A., Trautmann M. E., Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics 2007 29 11 2333 2348 2-s2.0-37349008890 10.1016/j.clinthera.2007.11.006 (Pubitemid 350298125)
31. Blevins T., Pullman J., Malloy J., Yan P., Taylor K., Schulteis C., Trautmann M., Porter L., DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2011 96 5 1301 1310 2-s2.0-79955661908 10.1210/jc.2010-2081
32. Bergenstal R. M., Wysham C., MacConell L., Malloy J., Walsh B., Yan P., Wilhelm K., Malone J., Porter L. E., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet 2010 376 9739 431 439 2-s2.0-77955573674 10.1016/S0140-6736(10)60590-9
33. Bunck M. C., Diamant M., Cornér A., Eliasson B., Malloy J. L., Shaginian R. M., Deng W., Kendall D. M., Taskinen M. R., Smith U., Yki-Järvinen H., Heine R. J., One-year treatment with exenatide improves β -cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009 32 5 762 768 2-s2.0-65949122087 10.2337/dc08-1797
34. Buse J. B., Henry R. R., Han J., Kim D. D., Fineman M. S., Baron A. D., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 11 2628 2635 2-s2.0-7444228521 10.2337/diacare.27.11.2628 (Pubitemid 39441462)
35. Buse J. B., Bergenstal R. M., Glass L. C., Heilmann C. R., Lewis M. S., Kwan A. Y. M., Hoogwerf B. J., Rosenstock J., Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. Annals of Internal Medicine 2011 154 2 103 112 2-s2.0-79551615182
36. Davies M. J., Donnelly R., Barnett A. H., Jones S., Nicolay C., Kilcoyne A., Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes, Obesity and Metabolism 2009 11 12 1153 1162 2-s2.0-70450199755 10.1111/j.1463-1326.2009.01154.x
37. DeFronzo R. A., Ratner R. E., Han J., Kim D. D., Fineman M. S., Baron A. D., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2. Diabetes Care 2005 28 5 1092 1100 2-s2.0-18144401971 10.2337/diacare.28.5.1092 (Pubitemid 40616618)
38. DeFronzo R. A., Triplitt C., Qu Y., Lewis M. S., Maggs D., Glass L. C., Effects of exenatide plus rosiglitazone on β -cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010 33 5 951 957 2-s2.0-77954897689 10.2337/dc09-1521
39. Diamant M., Van Gaal L., Stranks S., Northrup J., Cao D., Taylor K., Trautmann M., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet 2010 375 9733 2234 2243 2-s2.0-77953859640 10.1016/S0140-6736(10)60406-0
40. Drucker D. J., Buse J. B., Taylor K., Kendall D. M., Trautmann M., Zhuang D., Porter L., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. The Lancet 2008 372 9645 1240 1250 2-s2.0-53249142132 10.1016/S0140-6736(08)61206-4
41. Fineman M. S., Bicsak T. A., Shen L. Z., Taylor K., Gaines E., Varns A., Kim D., Baron A. D., Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003 26 8 2370 2377 2-s2.0-0037850667 10.2337/diacare.26.8.2370 (Pubitemid 36993328)
42. Gallwitz B., Böhmer M., Segiet T., Mölle A., Milek K., Becker B., Helsberg K., Petto H., Peters N., Bachmann O., Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 2011 34 3 604 606 2-s2.0-79956151964 10.2337/dc10-1900
43. Gao Y., Yoon K. H., Chuang L. M., Mohan V., Ning G., Shah S., Jang H. C., Wu T. J., Johns D., Northrup J., Brodows R., Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Research and Clinical Practice 2009 83 1 69 76 2-s2.0-57949096314 10.1016/j.diabres.2008.09.037
44. Gill A., Hoogwerf B. J., Burger J., Bruce S., MacConell L., Yan P., Braun D., Giaconia J., Malone J., Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovascular Diabetology 2010 9, article 6 2-s2.0-76949099016 10.1186/1475-2840-9-6
45. Heine R. J., Van Gaal L. F., Johns D., Mihm M. J., Widel M. H., Brodows R. G., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2005 143 8 559 I30 2-s2.0-26944477362
46. Kadowaki T., Namba M., Yamamura A., Sowa H., Wolka A. M., Brodows R. G., Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine Journal 2009 56 3 415 424 2-s2.0-67650490677 10.1507/endocrj.K08E-296
47. Kendall D. M., Riddle M. C., Rosenstock J., Zhuang D., Kim D. D., Fineman M. S., Baron A. D., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 5 1083 1091 2-s2.0-17144371646 10.2337/diacare.28.5.1083 (Pubitemid 40616617)
48. Kim D., MacConell L., Zhuang D., Kothare P. A., Trautmann M., Fineman M., Taylor K., Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007 30 6 1487 1493 2-s2.0-34249891874 10.2337/dc06-2375 (Pubitemid 46871159)
49. Liutkus J., Rosas Guzman J., Norwood P., Pop L., Northrup J., Cao D., Trautmann M., A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes, Obesity and Metabolism 2010 12 12 1058 1065 2-s2.0-77958540163 10.1111/j.1463-1326.2010. 01251.x
50. Moretto T. J., Milton D. R., Ridge T. D., MacConell L. A., Okerson T., Wolka A. M., Brodows R. G., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2008 30 8 1448 1460 2-s2.0-51549095571 10.1016/j.clinthera.2008.08. 006
51. Nauck M. A., Duran S., Kim D., Johns D., Northrup J., Festa A., Brodows R., Trautmann M., A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007 50 2 259 267 2-s2.0-34247195226 10.1007/s00125-006-0510-2
52. Schnell O., Otter W., Standl E., The Munich Myocardial Infarction Registry: translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice. Diabetes care 2009 32 S326 330 2-s2.0-75549087542
53. Poon T., Nelson P., Shen L., Mihm M., Taylor K., Fineman M., Kim D., Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technology and Therapeutics 2005 7 3 467 477 2-s2.0-20544476444 10.1089/dia.2005.7.467 (Pubitemid 40847809)
54. Zinman B., Hoogwerf B. J., Durán García S., Milton D. R., Giaconia J. M., Kim D. D., Trautmann M. E., Brodows R. G., The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 2007 146 7 477 485 2-s2.0-34247259577 (Pubitemid 351650556)
55. Buse J. B., Rosenstock J., Sesti G., Schmidt W. E., Montanya E., Brett J. H., Zychma M., Blonde L., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009 374 9683 39 47 2-s2.0-67649666737 10.1016/S0140-6736(09)60659-0
56. Garber A., Henry R., Ratner R., Garcia-Hernandez P. A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P. M., Zdravkovic M., Bode B., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet 2009 373 9662 473 481 2-s2.0-59449101432 10.1016/S0140-6736(08)61246-5
57. Marre M., Shaw J., Brändle M., Bebakar W. M. W., Kamaruddin N. A., Strand J., Zdravkovic M., Le Thi T. D., Colagiuri S., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009 26 3 268 278 2-s2.0-62449129181 10.1111/j.1464-5491.2009.02666.x
58. Nauck M., Frid A., Hermansen K., Shah N. S., Tankova T., Mitha I. H., Zdravkovic M., Düring M., Matthews D. R., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009 32 1 84 90 2-s2.0-62449169287 10.2337/dc08-1355
59. Pratley R., Nauck M., Bailey T., Montanya E., Cuddihy R., Filetti S., Garber A., Thomsen A. B., Hartvig H., Davies M., One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. International Journal of Clinical Practice 2011 65 4 397 407 2-s2.0-79952755181 10.1111/j.1742-1241.2011.02656.x
60. Russell-Jones D., Vaag A., Schmitz O., Sethi B. K., Lalic N., Antic S., Zdravkovic M., Ravn G. M., Simó R., Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009 52 10 2046 2055 2-s2.0-69949117621 10.1007/s00125-009-1472-y
61. Yang W., Chen L., Ji Q., Liu X., Ma J., Tandon N., Bhattacharyya A., Kumar A., Kim K., Yoon K., Bech O. M., Zychma M., Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes, Obesity and Metabolism 2011 13 1 81 88 2-s2.0-78649709557 10.1111/j.1463-1326.2010.01323.x
62. Zinman B., Gerich J., Buse J. B., Lewin A., Schwartz S., Raskin P., Hale P. M., Zdravkovic M., Blonde L., Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Erratum in Diabetes Care, vol. 33, p.692, 2010). Diabetes Care 2009 32 7 1224 1230
63. Feldman M., Schiller L. R., Disorders of gastrointestinal motility associated with diabetes mellitus. Annals of Internal Medicine 1983 98 3 378 384 2-s2.0-0020686499 (Pubitemid 13158511)
64. Ko G. T. C., Chan W. B., Chan J. C. N., Tsang L. W. W., Cockram C. S., Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus. Diabetic Medicine 1999 16 8 670 674 2-s2.0-0032703085 10.1046/j.1464-5491.1999. 00135.x
65. Ebert E. C., Gastrointestinal complications of diabetes mellitus. Disease-a-Month 2005 51 12 620 663 2-s2.0-31844432122 10.1016/j.disamonth.2005. 11.002 (Pubitemid 43183740)
66. Sogabe M., Okahisa T., Tsujigami K., Okita Y., Hayashi H., Taniki T., Hukuno H., Nakasono M., Muguruma N., Okamura S., Ito S., Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control. Journal of Gastroenterology 2005 40 6 583 590 2-s2.0-22844449471 10.1007/s00535-005-1592-1 (Pubitemid 41038787)
67. Chandrasekharan B., Anitha M., Blatt R., Shahnavaz N., Kooby D., Staley C., Mwangi S., Jones D. P., Sitaraman S. V., Srinivasan S., Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterology and Motility 2011 23 2 131 138 2-s2.0-78651419160 10.1111/j.1365-2982.2010.01611.x
68. Holst J. J., McGill M. A., Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clinical Drug Investigation 2012 32 1 1 14
69. Rafferty E. P., Wylie A. R., Hand K. H., Elliott C. E., Grieve D. J., Green B. D., Investigating the effects of physiological bile acids on GLP-1 secretion and glucose tolerance in normal and GLP-1R-/- mice. Biological Chemistry 2011 392 6 539 546 2-s2.0-79958030988 10.1515/BC.2011.050
70. Bytzer P., Talley N. J., Jones M. P., Horowitz M., Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Alimentary Pharmacology and Therapeutics 2001 15 1 137 142 2-s2.0-0035186582 10.1046/j.1365-2036.2001.00896.x (Pubitemid 32055594)
71. Quan C., Talley N. J., Jones M. P., Spies J., Horowitz M., Gain and loss of gastrointestinal symptoms in diabetes mellitus: associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up. American Journal of Gastroenterology 2008 103 8 2023 2030 2-s2.0-49349109994 10.1111/j.1572-0241.2008.01943.x
72. Barceló A., Rajpathak S., Incidence and prevalence of diabetes mellitus in the Americas. Revista Panamericana de Salud Publica 2001 10 5 300 308 2-s2.0-0035200034 (Pubitemid 33143952)
73. Jones K. L., Doran S. M., Hveem K., Dylan F., Bartholomeusz L., Morley J. E., Wei Ming Sun, Chatterton B. E., Horowitz M., Relation between postprandial satiation and antral area in normal subjects. American Journal of Clinical Nutrition 1997 66 1 127 132 2-s2.0-0030986798 (Pubitemid 27278910)
74. Sturm K., Parker B., Wishart J., Feinle-Bisset C., Jones K. L., Chapman I., Horowitz M., Energy intake and appetite are related to antral area in healthy young and older subjects. American Journal of Clinical Nutrition 2004 80 3 656 667 2-s2.0-4544374217 (Pubitemid 41115531)
75. Hveem K., Jones K. L., Chatterton B. E., Horowitz M., Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996 38 6 816 821 2-s2.0-0030016325 (Pubitemid 26231762)
76. Deacon C. F., Potential of liraglutide in the treatment of patients with type 2 diabetes. Vascular Health and Risk Management 2009 5 199 211 2-s2.0-67449096006
77. Macconell L., Brown C., Gurney K., Han J., Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes, Metabolic Syndrome and Obesity 2012 5 29 41
78. Nelson P., Poon T., Guan X., Schnabel C., Wintle M., Fineman M., The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technology and Therapeutics 2007 9 4 317 326 2-s2.0-34548321003 10.1089/dia.2006.0024 (Pubitemid 47340082)
79. Buse J. B., Sesti G., Schmidt W. E., Montanya E., Chang C. T., Xu Y., Blonde L., Rosenstock J., Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010 33 6 1300 1303 2-s2.0-77956076972 10.2337/dc09-2260
80. Vilsbøll T., Krarup T., Madsbad S., Holst J. J., No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetic Medicine 2001 18 2 144 149 2-s2.0-0035081369 10.1046/j.1464-5491.2001.00424.x (Pubitemid 32238961)
81. Agersø H., Vicini P., Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. European Journal of Pharmaceutical Sciences 2003 19 2-3 141 150 2-s2.0-0037844361 10.1016/S0928-0987(03)00073-3 (Pubitemid 36668041)
82. Caldwell D. M., Ades A. E., Higgins J. P. T., Simultaneous comparison of multiple treatments: combining direct and indirect evidence. British Medical Journal 2005 331 7521 897 900 2-s2.0-26944454062 (Pubitemid 41502718)